Lupin and PolyPeptide Form Alliance to Enhance Peptide Supply Chain

Lupin Manufacturing Solutions, a subsidiary of Lupin Limited, has announced a strategic alliance with PolyPeptide Group AG, a specialized contract development and manufacturing organization (CDMO) for peptide-based active pharmaceutical ingredients. The alliance aims to enhance the global peptide supply chain, focusing on improving supply chain resilience and operational efficiency. This collaboration is intended to support the rapidly expanding global peptides market and advance next-generation peptide therapeutics, including those for metabolic diseases.

The financial terms of the alliance between Lupin Manufacturing Solutions and PolyPeptide have not been disclosed in the filing. The partnership is structured to enhance the capabilities of both companies in the peptide supply chain. By integrating procurement and supply planning, the alliance seeks to ensure unwavering quality and reliability in delivering peptide APIs globally. The collaboration is expected to fortify peptide supply chains to meet the rising global demand for these ingredients, particularly in metabolic disease therapies.

The scope of the alliance includes expanding sourcing options and integrating procurement and supply planning. Both companies will work towards ensuring quality and reliability in the supply of peptide APIs. The partnership is designed to enhance Lupin Manufacturing Solutions as a leading CDMO supplier of peptide materials for both innovator and generic markets. PolyPeptide aims to strengthen its position as a trusted CDMO partner through this collaboration. The alliance will focus on delivering superior service globally and supporting the long-term strategic growth of both organizations.

The market context for this alliance is the rapidly growing demand for peptide-based therapies, particularly in the treatment of metabolic and other chronic conditions. The collaboration between Lupin Manufacturing Solutions and PolyPeptide is positioned to address this demand by ensuring reliable access to specialized materials that support large-scale commercial production. The alliance underscores the commitment of both companies to establish secure and agile supply pathways for innovators worldwide.

The timeline for the implementation of the strategic alliance has not been specified in the filing. However, both Lupin Manufacturing Solutions and PolyPeptide are expected to begin working on expanding sourcing options and integrating procurement and supply planning immediately. The partnership will focus on ensuring quality and reliability in the supply of peptide APIs to meet the growing global demand.

PolyPeptide Group AG is a specialized CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients. The company supports its customers in the pharma and biotech sectors, contributing to the health of millions of patients worldwide. PolyPeptide operates a global network of six GMP-certified facilities in Europe, the U.S., and India, serving a fast-growing market with significant exposure to metabolic diseases.

Lupin Limited is a global pharmaceutical company focused on the development and manufacturing of a wide range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company is committed to leveraging its scientific rigor and regulatory expertise to support biopharma innovators from early development to commercial scale. Lupin aims to accelerate the path to market for transformative therapies through its subsidiary, Lupin Manufacturing Solutions.